Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Go back to Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting| (NASDAQ: CRDF) | Delayed: 1.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.25 | 52 Week High | $ | |||
| Open | $1.25 | 52 Week Low | $ | |||
| Day High | $1.25 | P/E | N/A | |||
| Day Low | $1.25 | EPS | $ | |||
| Volume | 692 | |||||
